ImmunoCellular Therapeutics Number Of Shares Shorted vs. Shares Owned By Insiders
Based on ImmunoCellular Therapeutics' profitability indicators, ImmunoCellular Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess ImmunoCellular Therapeutics' ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Please note, there is a significant difference between ImmunoCellular Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunoCellular Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunoCellular Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For ImmunoCellular Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunoCellular Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunoCellular Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunoCellular Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunoCellular Therapeutics over time as well as its relative position and ranking within its peers.
ImmunoCellular |
ImmunoCellular Therapeutics Shares Owned By Insiders vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoCellular Therapeutics's current stock value. Our valuation model uses many indicators to compare ImmunoCellular Therapeutics value to that of its competitors to determine the firm's financial worth. ImmunoCellular Therapeutics is rated fifth overall in number of shares shorted category among its peers. It is currently regarded as number one stock in shares owned by insiders category among its peers . The ratio of Number Of Shares Shorted to Shares Owned By Insiders for ImmunoCellular Therapeutics is about 1,748 . Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoCellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoCellular Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.ImmunoCellular Shares Owned By Insiders vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
ImmunoCellular Therapeutics |
| = | 165.95 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
ImmunoCellular Therapeutics |
| = | 94.96 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
ImmunoCellular Shares Owned By Insiders Comparison
ImmunoCellular Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
ImmunoCellular Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunoCellular Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunoCellular Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of ImmunoCellular Therapeutics' change in net profit over the period of time. It can combine multiple indicators of ImmunoCellular Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
ImmunoCellular Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmunoCellular Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunoCellular Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunoCellular Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in ImmunoCellular Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Use Investing Themes to Complement your ImmunoCellular Therapeutics position
In addition to having ImmunoCellular Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |